300 related articles for article (PubMed ID: 34863080)
61. DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway.
Wei X; Mao T; Li S; He J; Hou X; Li H; Zhan M; Yang X; Li R; Xiao J; Yuan S; Sun L
Phytomedicine; 2019 Feb; 54():120-131. PubMed ID: 30668361
[TBL] [Abstract][Full Text] [Related]
62. Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts.
Liu Y; Zhang W; Wang XJ; Liu S
BMC Complement Altern Med; 2014 Jul; 14():228. PubMed ID: 25005526
[TBL] [Abstract][Full Text] [Related]
63. Baohuoside-1 targeting mTOR inducing apoptsis to inhibit hepatocellular carcinoma proliferation, invasion and migration.
Guo Y; Zhu H; Weng M; Chen B; Wang C; Sun L
Biomed Pharmacother; 2020 Aug; 128():110366. PubMed ID: 32526459
[TBL] [Abstract][Full Text] [Related]
64. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
65. microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
Ouyang H; Gore J; Deitz S; Korc M
Oncogene; 2014 Sep; 33(38):4664-74. PubMed ID: 24096486
[TBL] [Abstract][Full Text] [Related]
66. Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1α pathways under hypoxia.
Onishi H; Morisaki T; Nakao F; Odate S; Morisaki T; Katano M
Cancer Lett; 2013 Jul; 335(2):289-98. PubMed ID: 23485726
[TBL] [Abstract][Full Text] [Related]
67. Metformin reduces pancreatic cancer cell proliferation and increases apoptosis through MTOR signaling pathway and its dose-effect relationship.
Zhao HW; Zhou N; Jin F; Wang R; Zhao JQ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5336-5344. PubMed ID: 32495867
[TBL] [Abstract][Full Text] [Related]
68. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
[TBL] [Abstract][Full Text] [Related]
69. The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells.
Ye Z; Li Y; Xie J; Feng Z; Yang X; Wu Y; Zhao K; Pu Y; Xu X; Zhu Z; Li W; Pan J; Chen W; Xing C
Anticancer Agents Med Chem; 2020; 20(12):1447-1458. PubMed ID: 32384038
[TBL] [Abstract][Full Text] [Related]
70. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.
Diersch S; Wenzel P; Szameitat M; Eser P; Paul MC; Seidler B; Eser S; Messer M; Reichert M; Pagel P; Esposito I; Schmid RM; Saur D; Schneider G
Oncotarget; 2013 Feb; 4(2):277-88. PubMed ID: 23470560
[TBL] [Abstract][Full Text] [Related]
71. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma.
Li Y; Zheng Z; Xiao L; Chen Y; Liu X; Long D; Chai L; Li Y; Tan C
Anticancer Drugs; 2024 Feb; 35(2):140-154. PubMed ID: 37694833
[TBL] [Abstract][Full Text] [Related]
72. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
[TBL] [Abstract][Full Text] [Related]
73. A Critical Review on Anticancer Mechanisms of Natural Flavonoid Puerarin.
Murahari M; Singh V; Chaubey P; Suvarna V
Anticancer Agents Med Chem; 2020; 20(6):678-686. PubMed ID: 32106804
[TBL] [Abstract][Full Text] [Related]
74. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
75. Polyphyllin I Promoted Melanoma Cells Autophagy and Apoptosis via PI3K/Akt/mTOR Signaling Pathway.
Long J; Pi X
Biomed Res Int; 2020; 2020():5149417. PubMed ID: 32733943
[TBL] [Abstract][Full Text] [Related]
76. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
77. LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR-539.
Nai Y; Pan C; Hu X; Ma Y
Cancer Med; 2020 Jan; 9(2):757-767. PubMed ID: 31789465
[TBL] [Abstract][Full Text] [Related]
78. AKT and mTOR expression in human pancreatic ductal adenocarcinoma. Relevance for tumor biology.
Handra-Luca A
Pathol Res Pract; 2023 Nov; 251():154878. PubMed ID: 37890271
[TBL] [Abstract][Full Text] [Related]
79. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
80. Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).
Babiker HM; Karass M; Recio-Boiles A; Chandana SR; McBride A; Mahadevan D
Expert Opin Investig Drugs; 2019 Jul; 28(7):583-592. PubMed ID: 31215251
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
